Long-lasting attenuation of amygdala-kindled seizures after convection-enhanced delivery of botulinum neurotoxins A and B into the amygdala in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 346, Issue 3, 2013, Pages 528-534

  Gasior, Maciej ^a   Tang, Rebecca ^a   Rogawski, Michael A ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BASOLATERAL AMYGDALA; BODY TEMPERATURE; BRAIN PROTECTION; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG POTENCY; ELECTROENCEPHALOGRAPHY; EXCITABILITY; KINDLING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

AMYGDALA; ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; BODY TEMPERATURE; BOTULINUM TOXINS; BOTULINUM TOXINS, TYPE A; CONVECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; KINDLING, NEUROLOGIC; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES;

EID: 84882421959     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205070     Document Type: Article

References (40)

1. Anschel DJ, Ortega EL, Kraus AC, and Fisher RS (2004) Focall y injected adenosine prevents seizures in the rat. Exp Neurol 190:544-547.
2. Antonucci F, Bozzi Y, and Caleo M (2009) Intrahippocampal infusion of botulinum neurotoxin E (BoNT/E) reduces spontaneous recurrent seizures in a mouse model of mesial temporal lobe epilepsy. Epilepsia 50:963-966.
3. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, and Caleo M (2008) Longdistance retrograde effects of botulinum neurotoxin A. J Neurosci 28:3689-3696.
4. Ashton AC and Dolly JO (1988) Characterization of t he inhibitory action of botulinum neurotoxin type A on the release of several transmitters from rat cerebrocortical synaptosomes. J Neurochem 50:1808-1816.
5. Bigalke H, Heller I, Bizzini B, and Habermann E (19 81) Tetanus toxin and botulinum A toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord. Naunyn Schmiedebergs Arch Pharmacol 316:244-251.
6. Blitzer A (2005) Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg 133:836-838.
7. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, and Oldfi eld EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91:2076-2080.
8. Bozzi Y, Costantin L, Antonucci F, and Caleo M (2006) Action of botulinum neuroto xins in the central nervous system: antiepileptic effects. Neurotox Res 9:197-203.
9. Caleo M, Antonucci F, Restani L, and Mazzocchio R (2009) A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem 109:15-24.
10. Capogna M, McKinney RA, O?Connor V, Gähwiler BH, and Thompson SM (1997) Ca21 or Sr21 partially rescues synaptic transmission in hippocampal cultures treated with botulinum toxin A and C, but not tetanus toxin. J Neurosci 17: 7190-7202.
11. Chen MY, Lonser RR, Morrison PF, Governale LS, and Oldfield EH (1999) Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 90:315-320 .
12. Costantin L, Bozzi Y, Richichi C, Viegi A, Antonucci F, Funicello M, Gobbi M, Mennini T, Rossetto O, and Montecucco C,, et al. (2005) Antiepileptic effects of botulinum neurotoxin E. J Neurosci 25:1943-1951.
13. Eder HG, Stein A, and Fisher RS (1997) Interictal and ictal activity in the rat cobalt/ pilocarpine model of epilepsy decreased by local perfusion of diazepam. Epilepsy Res 29:17-24.
14. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, and Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135-138.
15. Fisher RS and Chen DK (2006) New routes for delivery of anti-epileptic medications. Acta Neurol Taiwan 15:225-231.
16. Flynn TC and Clark RE, II (2003) Botulinum toxi n type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29:519-522, discussion 522.
17. Foran PG, Mohammed N, Lisk GO, Nagwaney S, Lawrence GW, Johnson E, Smith L, Aoki KR, and Dolly JO (2003) Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A: basis for distinct durations of inhibition of exocyto sis in central neurons. J Biol Chem278:1363-1371.
18. Freeman FG and Jarvis MF (1981) The effect of interstimulation interval on the assessment and stability of kindled seizure thresholds. Brain Res Bull 7:629-633.
19. Gasior M, White NA, and Rogawski MA (2007) Prolonged attenuation of amygdalakindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists v-conotoxin GVIA and v-conotox in MVIIA. J Pharmacol Exp Ther 323:458-468.
20. Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R, Siciliani L, Sabatelli M, and Bentivoglio AR (2011) Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson? s disease. Mov Disord 26:313-319.
21. Habermann E, Müller H, and Hudel M (1988) Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain. J Neurochem 51:522-527.
22. Keller JE, Neale EA, Oyler G, and Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137-142.
23. Ludvig N, Medveczky G, French JA, Carlson C, Devinsky O, and Kuzniecky RI (2010) Evolution and prospects for intracranial pharmacotherapy for refractory epilepsies: the subdural hybrid neuroprosthesis. Epilepsy Res Treat 2010:725696.
24. Luvisetto S, Marinelli S, Rossetto O, Montecucco C, and Pavone F (2004) Central injection of botulinum neurotoxins: behavioural effects in mice. Behav Pharmacol 15:233-240.
25. Luvisetto S, Rossetto O, Montecucco C, and Pavone F (2003) Toxicity of botulinum neurotoxins in central nervous system of mice. Toxicon 41:475-481.
26. Nilsen KE and Cock HR (2004) Focal treatment for refractory epilepsy: hope for the future? Brain Res Brain Res Rev 44:141-153.
27. Pappert EJ and Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group (2008) Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 23: 510-517.
28. Paxinos G and Watson C (1998) The Rat Brain in Stereotaxic Coordinates, 4th ed. Academic Press, Sydney.
29. Pinel JP, Skelton R, and Mucha RF (1976) Kindling-related changes in afterdischarge " thresholds". Epilepsia 17:197-206.
30. Racine RJ (1972) Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281-294.
31. Rogawski MA (2009) Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 6:344-351.
32. Rossetto O, Seveso M, Caccin P, Schiavo G, and Montecucco C (2001) Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 39:27-41.
33. Simpson LL (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44:167-193.
34. Sloop RR, Cole BA, and Escutin RO (1997) Human response to botulinum toxin injection: type B compared with type A. Neurology 49:189-194.
35. Stein AG, Eder HG, Blum DE, Drachev A, and Fisher RS (2000) An automated drug delivery system for focal epilepsy. Epilepsy Res 39:103-114.
36. Tsai YC, Maditz R, Kuo CL, Fishman PS, Shoemaker CB, Oyler GA, and Weissman AM (2010) Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA 107:16554-16559.
37. Verderio C, Grumelli C, Raiteri L, Coco S, Paluzzi S, Caccin P, Rossetto O, Bonanno G, Montecucco C, and Matteoli M (2007) Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8:142-153.
38. Verderio C, Pozzi D, Pravettoni E, Inverardi F, Schenk U, Coco S, Proux-Gillardeaux V, Galli T, Rossetto O, and Frassoni C, et al. (2004) SNAP-25 modulation of calcium dynamics underlies differences in GABAergic and glutamatergic responsiveness to depolarization. Neuron 41:599-610.
39. Wang J, Zurawski TH, Meng J, Lawrence G, Olango WM, Finn DP, Wheeler L, and Dolly JO (2011) A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 286:6375-6385.
40. Wiegand H, Erdmann G, and Wellhöner HH (1976) 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292:161-165.